To circumvent the CD47-SIRPα interaction and phagocytosis inhibition, Alvey et al. [68] engineered human bone marrow derived macrophages to inhibit SIRPα (THP-1 SIRPα KD) and to express specific antibodies on anti-cancer cells (anti-MUC1, Cetuximab), so-called “A’PB macrophages”. This evidence concerns the gene SIRPA and cancer.